Parallax Volatility Advisers
LGND icon

Parallax Volatility Advisers’s Ligand Pharmaceuticals LGND Stock Holding History

Parallax Volatility Advisers’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-48,090
Closed -$4.11M – 3389
2017
Q4 		$4.11M Hold
48,090
– – 0.01% 673
2017
Q3 		$4.08M Buy
+48,090
New +$3.81M 0.01% 624

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Parallax Volatility Advisers's LGND Position: Q1 2019 in Review

Parallax Volatility Advisers sold out of Ligand Pharmaceuticals (LGND) in Q1 2019, closing a stake of 1,666 shares — an estimated $141K sold.

Parallax Volatility Advisers first reported a position in LGND in Q3 2017 and held it in 5 quarters. The position peaked at $1.17M in Q3 2017. 330 funds tracked by Wall St. Rank hold LGND as of Q1 2019.

  • Parallax Volatility Advisers reported no remaining Ligand Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Parallax Volatility Advisers sold 1,666 Ligand Pharmaceuticals shares in Q1 2019, an estimated $141K.
  • Parallax Volatility Advisers first reported a position in Ligand Pharmaceuticals in Q3 2017 and held it in 5 quarters.
  • Parallax Volatility Advisers's Ligand Pharmaceuticals position peaked at $1.17M in Q3 2017.
  • 330 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2019.

Based on Parallax Volatility Advisers's 13F filing for Q1 2019, filed 15 May 2019.